Participated · Series B · Aug 2026

BEI develops and manufactures anode-free lithium metal batteries designed for high energy density and power; its current-generation cells exceed 500 Wh/kg according to the company. Independent testing by About:Energy confirmed leading energy density and power characteristics, and a BEI-powered drone demonstrated over 30 minutes of flight at −26°C during a field demo in Finland. BEI reports more than 30 global UAV customers are evaluating or deploying its cells, which are already integrated into operational small unmanned systems. The company is commercially shipping its AFLMB cells today while advancing a roadmap targeting future cell generations with energy densities above 600 Wh/kg. With the Series B proceeds, BEI plans to scale manufacturing, run customer qualification programs, and expand commercially across Korea, the U.S., and Europe. Strategic partnerships and investor relationships aim to strengthen supply-chain resilience and support adoption in defense, robotics, and electric mobility markets.

Participated · Series B · Jul 2026

Founded in 2015 by CEO Chulsoon Park, WiseJet develops 60GHz millimeter-wave chipsets intended to replace cables and connectors with near-zero delay wireless links. Its product lineup includes a near-field connector chip (WC6) and a video chip (WV6) currently implemented on an FPGA and planned for ASIC conversion. The company showcased wireless robot-joint solutions and 8K/60Hz video at CES 2025, drawing interest from more than 110 companies and follow-up talks with around 50 global robotics and home-appliance firms, and demonstrated DisplayPort video over 10 meters at CES 2026. WiseJet aims to move both chips into mass production across the remainder of this year and next, and is preparing for a technology-based special listing in 2028. Financially, the company has raised a cumulative KRW 14 billion after the most recent KRW 5 billion pre-Series B round and is using the new funds to finalize production readiness and expand R&D.

Participated · Series A · Apr 2021

ImpriMed develops AI-powered live-cell drug sensitivity and predictive models to identify effective anticancer medicines for individual canine and feline blood cancers. Its core service measures live tumor-cell responses in a California lab and combines those measurements with biological data to produce a treatment report delivered to veterinarians within seven days. Veterinary services are fully commercialized (five canine and three feline services), generate revenue, and have been used by more than 350 U.S. veterinarians; the company says it has helped over 5,000 dogs with lymphoma and collected outcome follow-up on over half of those cases. ImpriMed has run validation work with data from 2,000 human blood-cancer patients and the Mayo Clinic Platform’s 3 million‑patient database. The company plans to expand its veterinary-to-human precision oncology efforts, with an AI multiple myeloma product targeting commercialization in 2025 and plans to commercialize services for human AML and non-Hodgkin’s lymphoma before the end of 2024. It also offers a live-cell CRO service to help drug developers measure compound efficacy on patient cells. The startup plans to use new funding to expand its drug-response prediction technology into human oncology, grow its team (about 40 staff) and broaden business-development pipelines. ImpriMed is a Palo Alto-based veterinary precision medicine company that uses artificial intelligence to predict which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia. It generates live data from chemosensitivity and immunophenotyping assays on patients’ fresh cancer cells to produce quantified drug response predictions for veterinary oncologists. Led by CEO and co‑founder Dr. Sungwon Lim, the company enables clinicians to make chemotherapy decisions with greater confidence prior to drug administration. To date ImpriMed has provided more than 2,000 services to community-treated canine patients. The company plans to use the new funding to develop additional prediction models for its current canine blood-cancer targets, scale up its customer network and expand pipelines to other types of cancers in dogs and cats. Financially, ImpriMed closed an $8m Pre-Series A round comprising $7.7m from venture capital investors and the remainder as a government grant. ImpriMed uses precision medicine techniques to test hundreds of drug responses on fresh biopsy samples from canine cancer patients, observing how live cancer cells react before treatment. The platform screens for the most effective chemotherapy options and excludes non-effective ones, then provides those results to veterinary oncologists. The company is currently focused on treating lymphoma in dogs. ImpriMed plans to roll out a clinical trial that will be performed primarily at SAGE Veterinary Centers in the Bay Area. For a limited time it is offering its service free of charge while completing the clinical trial and aims to help more than 500 dogs by 2020. The company was founded in 2017 and maintains an additional presence in Seoul, South Korea.